Skip to main content

Day: April 5, 2025

Ingalls Shipbuilding Hosts Second Annual Scouts Merit Badge Day

PASCAGOULA, Miss., April 05, 2025 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division welcomed more than 80 Scouts from Mississippi, Alabama, and as far north as Kentucky and Tennessee for its second annual Scouts merit badge day at the Ingalls Maritime Training Academy. The event, designed to inspire and support the next generation of leaders, provided Scouts the opportunity to explore shipbuilding career interests and gain hands-on experience in various technical fields found at Ingalls. “We are grateful to host this event again at Ingalls and to see so many returning and new Scouts this year,” Ingalls Shipbuilding Community Relations Manager Lisa Bradley said. “Scouting builds character, leadership, and technical skills that align closely with what we value in our Ingalls workforce and it’s an honor to be able...

Continue reading

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer’s disease Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73)...

Continue reading

GOGL – Appointment of CEO and CFO

The Board of Golden Ocean Group Ltd. (“Golden Ocean” or the “Company”) is pleased to announce the appointment of Mr. Peder Simonsen as the Chief Executive Officer of Golden Ocean Management AS. Mr. Simonsen currently serves as the Interim Chief Executive Officer and Chief Financial Officer of Golden Ocean Management AS. Further, the Company is pleased to announce the appointment of Ms. Randi Navdal Bekkelund as Chief Financial Officer of Golden Ocean Management. Ms. Bekkelund currently serves as the Chief Financial Officer of Avance Gas Holding Ltd. Ms. Bekkelund will commence her new role on June 1, 2025. April 5, 2025 The Board of DirectorsGolden Ocean Group Ltd.Hamilton, Bermuda This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.  

Continue reading

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3) Mean Decrease of 79% in Mutant Z-AAT Observed at Day 28 in 60 mg Cohort (n=3) Fourth Cohort Evaluating 75 mg of BEAM-302 Initiated, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at a Medical Conference in Second Half of 2025 CAMBRIDGE, Mass., April 05, 2025 (GLOBE NEWSWIRE) —  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress, taking place April 4-5,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.